Sen-Jam Pharmaceutical Positions SJP-002C as a Transformative Complement to GLP-1 Therapies and a Standalone Solution for MASH

HUNTINGTON, N.Y., Aug. 12, 2025 /PRNewswire/ -- Sen-Jam Pharmaceutical today announced significant progress in advancing its innovative immuno-regulator platform aimed at addressing the critical "durability gap" in obesity care and delivering novel therapeutic solutions for MASH (Metabolic Associated Steatohepatitis).

Following a successful Phase 2 trial demonstrating a placebo-equivalent side effect profile, SJP-002C is positioned for rapid clinical advancement as both a standalone therapy and a synergistic partner to GLP-1 treatments. The company has finalized an FDA-ready CMC package and confirmed six-month stability data, enabling the immediate launch of a GLP-1 + SJP-002C Phase 2b clinical trial.

Mechanistic Innovation

SJP-002C is built on a multi-pronged anti-inflammatory engine that combines dual COX/cPLA₂ inhibition with mast cell stabilization—a uniquely synergistic approach rarely seen in metabolic drug development. This mechanism is designed to hit the metabolic dysfunction at its source—not just the symptoms, by:

• Interrupting lipid-driven inflammation — Reducing lipotoxicity, which damages liver and adipose tissue, fuels insulin resistance, and drives fibrosis progression in MASH. This mechanism has the potential benefit of reducing more fat loss per pound of weight loss.
  
  
• Rewiring inflammatory signaling — Blunting neuroinflammatory resistance that can limit the brain's response to weight loss signals, helping preserve hypothalamic sensitivity to leptin and insulin.
  
  
• Restoring metabolic "conversation" — Improving leptin and insulin signaling to better regulate hunger, satiety, and glucose metabolism, creating a stronger metabolic baseline for both weight maintenance and liver health.
  
  
• Stabilizing mast cells — Damping chronic, low-grade inflammation that contributes to disease persistence and GLP-1 weight regain once dosing is reduced or stopped. This mechanism can provide durability of weight loss, a significant need in the market.

By addressing both systemic inflammation and neuro-metabolic resistance, SJP-002C is designed as a metabolic durability enhancer—well-suited for combination with GLP-1 therapies or as a potent standalone treatment for MASH and obesity maintenance. 

Broad Clinical Potential

Sen-Jam's development plan includes:

• Obesity maintenance, with or without GLP-1 therapy
• MASH monotherapy for patients in F1–F2 stages
• Combination therapy with GLP-1 or resmetirom in advanced F2–F3 stages

With newly filed patents covering the Manufacturing Process and Treatment of Obesity and Metabolic Disorders, Sen-Jam has secured an IP runway extending into the 2040s.

A Strategic Partner Opportunity

Given the $367B global longevity market, Sen-Jam believes SJP-002C offers an unprecedented opportunity for the legacy GLP-1 pharma companies to extend exclusivity, differentiate GLP-1 portfolios, and expand into high-value adjacent markets such as MASH.

"Sen-Jam is tackling inflammation with a differentiated strategy that combines proven molecules with novel insights into inflammatory biology," said Dr. Francis Farraye, Advisory Board Member for Sen-Jam, Professor of Medicine and Director of the Inflammatory Bowel Disease Center at the Mayo Clinic in Jacksonville, Florida. "This approach—validated by its Phase 2 data of 2 weeks of SJP-002C in treatment of patients with acute COVID infection—represents a rare opportunity: a safe, scalable, and science-backed solution that is well-timed for a market eager for innovation in anti-inflammation therapeutics."

Manufacturing Excellence

Sen-Jam's corporate venture and manufacturing partner, KVK-Tech, has been instrumental in enabling the rapid clinical readiness of SJP-002C.

"Partnering with Sen-Jam on SJP-002C has been an exciting journey," said Kiran Vepuri, Executive Vice President of Business Development at KVK-Tech. "Their science-driven approach, combined with our technical expertise, creates a clear path to delivering a therapy that can enhance GLP-1 effectiveness and stand alone in critical unmet markets."

Pipeline Momentum

Sen-Jam's momentum extends beyond the clinic and into industry recognition. Recently spotlighted in the Oppenheimer Longevity Report as a standout in immuno-regulation and a next-generation leader in prevention medicine, the company is carving a place at the intersection of metabolic health, inflammation science, and longevity. This positioning underscores Sen-Jam's role as a disruptive force—bringing to market solutions designed not just to treat disease, but to rewire the trajectory of human health.

Building on this momentum, Sen-Jam is advancing its Phase 2 clinical trial for SJP-001, with IRB approval expected this week—another milestone in a rapidly expanding pipeline of science-backed, prevention-focused therapeutics.

About Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical is a clinical-stage biopharmaceutical company dedicated to developing safe, scalable, and science-backed anti-inflammatory solutions for conditions ranging from acute infections to chronic metabolic disorders.  By repurposing well-characterized small molecules through its proprietary delivery platform—and leveraging the FDA's accelerated 505(b)(2) regulatory pathway—Sen-Jam is building a new class of anti-inflammatories designed to target several inflammatory pathways upstream, unlike traditional blockbusters that reduce inflammation narrowly and risk immunosuppression.  This platform approach opens doors to faster clinical validation, broader indications, and therapies that are not only effective—but accessible, safe, and scalable. Investor information available at Wefunder. Learn more at www.sen-jam.com

Contact: 
Christine Leonard
Sen-Jam Pharmaceutical
781-913-1902
[email protected]

SOURCE Sen-Jam Pharmaceutical